



The 'No Compromise' immunoassay platform: PFLISA[™]



Empowering discovery through clinical workflows with ultrasensitive quantitation, absolute precision, accuracy, and reproducibility. The PFLISA[™] platform removes the need to choose between sensitivity, multiplex capability, and conserving precious sample. It rebalances what matters most: sample volume, plex flexibility, and ease of execution.



The PFLISA[™] assay platform is a true 'No Compromise' solution, combining industry-leading ultrasensitivity with consistent quantitation from singleplex to multiplex. No need to switch platforms as assays evolve or when focus switches to critical analytes.

With low sample volume requirements, more data is generated from precious specimens, while a wide dynamic range reduces reruns. Extended signal stability (≥ 12 hours) enables consistent handling across labs and automated workflows. All delivered within a scalable, familiar ELISA-like workflow, with the unique flexibility of rapid assay development for users' own antibody pairs.

Empower ● ● ●



The fully integrated PFLISA[™] assay platform:

- **Discovery Reader:** Robust design with precise readouts, easy user installation, and single-button operation
- **Empower Software:** Intuitive and intelligent easy data acquisition and automated analysis, compliance-ready
- **PFLISA-Plex[™]:** Pre-coated/validated multiplex plates designed for ultrasensitive quantitation and reproducibility
- **PFLISA-Focus[™]:** Pre-coated/validated multiplex plates, user-defined panels from defined libraries, for targeted quantitation
- **PFLISA-Flex[™]:** Singleplex 'own pair' homebrew, delivering ultrasensitivity from your antibody pairs

Breaking through traditional bottlenecks

Modern biopharmaceutical drug discovery and development requires exceptional analytical precision, at every stage. Legacy immunoassay platforms introduce critical operational and technical barriers that slow down, and even stall, development timelines and compromise data integrity at different stages of the process.

The PFLISA™ platform couples a familiar workflow with proprietary signal amplification technology that allows deployment throughout R&D, delivering consistent data, independent of plex and stage.

Uncover the undetectable

Femtogram sensitivity enables quantitation of challenging analytes like IL-1B, IL-4 or NfL in a multiplexed format. No compromise between sensitivity and plex, just clear, reliable quantitation of ultra-low abundance biomarker.

Maximise every drop

≤15 µL of precious sample for singleplex-level confidence at 1-12 plex, with minimal cross-talk or matrix effects. Quantitation without exhausting limited sample, eliminating the historical trade-off.

Acceleration at the bench

<1 week for a singleplex antibody pair assay development. Qualify assay in days, not months, to get the repeatable, reliable, robust data needed to make decisions.

Reliability without the rush

12-hour signal stability for consistent quantitation from tech to tech, lab to lab, lab to CRO. Ultra-stable signals and broad dynamic ranges that transition seamlessly from the bench to global CROs.

Time means money

4-5 log dynamic range across all panel sizes means fewer reruns, fewer errors, higher throughput = LESS TIME.

PFLISA™ Platform Features

Sensitivity	50-100x better than ELISA
Multiplex	2 to 12-plex
Dynamic Range	4-5 Log Orders
Reproducibility	Inter-/Intra-Assay CV <20%
Sample Size	15 µL or less
PFLISA-Flex™	Easy singleplex homebrew

For more information and
to request a demo:



Empowering researchers to see more with less
brightestbio.com

Brightest®
Bio ● ● ●